3 S&P 500 Stocks Walking a Fine Line

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Some large-cap stocks are past their peak, and StockStory is here to help you separate the winners from the laggards. Keeping that in mind, here are three S&P 500 stocks to steer clear of and a few alternatives to consider.

Builders FirstSource (BLDR)

Market Cap: $13.81 billion

Headquartered in Irving, TX, Builders FirstSource (NYSE:BLDR) is a construction materials manufacturer that offers a variety of lumber and lumber-related building products.

Why Is BLDR Not Exciting?

1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 4.9% annually over the last two years
2. Earnings per share have dipped by 24.8% annually over the past two years, which is concerning because stock prices follow EPS over the long term
3. Waning returns on capital imply its previous profit engines are losing steam

Builders FirstSource is trading at $124.91 per share, or 20.4x forward P/E. If you’re considering BLDR for your portfolio, see our FREE research report to learn more.

AMETEK (AME)

Market Cap: $48.74 billion

Started from its humble beginnings in motor repair, AMETEK (NYSE:AME) manufactures electronic devices used in industries like aerospace, power, and healthcare.

Why Does AME Give Us Pause?

1. Annual revenue growth of 5.1% over the last two years was below our standards for the industrials sector
2. Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth

At $211.74 per share, AMETEK trades at 26.8x forward P/E. Dive into our free research report to see why there are better opportunities than AME.

Bristol-Myers Squibb (BMY)

Market Cap: $113.8 billion

With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases.

Why Does BMY Worry Us?

1. Sizable revenue base leads to growth challenges as its 3.9% annual revenue increases over the last two years fell short of other healthcare companies
2. Estimated sales decline of 6.3% for the next 12 months implies a challenging demand environment
3. Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results

Bristol-Myers Squibb’s stock price of $55.94 implies a valuation ratio of 9.1x forward P/E. Check out our free in-depth research report to learn more about why BMY doesn’t pass our bar.

High-Quality Stocks for All Market Conditions

Check out the high-quality names we’ve flagged in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.